In our weekly series at The Acquirer’s Multiple, we dive into a stock that might be an undervalued gem. This week, we’re looking at Nutex Health Inc. (NUTX). They focus on healthcare delivery and hospital management, especially through micro-hospitals and specialty care across the U.S.
Nutex operates at the crossroads of healthcare services and infrastructure. They cater to the growing need for local, flexible acute care, which has been increasingly important in recent years. With changing patient expectations, Nutex’s model positions it well for the future.
Business Overview
Nutex employs a hybrid model that combines:
- Micro-hospital ownership and partnerships
- Hospital management services
- Value-based health programs
- Outpatient and specialty care facilities
This decentralized approach allows them to provide hospital-level care efficiently and closer to patients, which can be a crucial factor in emergency situations.
Understanding IV/P (Intrinsic Value to Price)
IV/P measures how a stock’s conservative valuation compares to its current trading price:
IV/P > 1 means it’s undervalued
IV/P < 1 means it's overvalued
NUTX’s IV/P sits at 3.20, suggesting it is valued around one-third of its possible worth. This reveals significant upside potential if the company sustains its growth and improves operational performance.
Financial Metrics
Let’s break down some key financial figures:
- Revenue (TTM): approx. US$ 981M
- Gross Profit: approx. US$ 540M
- Operating Income: approx. US$ 359M
- Net Income: approx. US$ 121M
- Free Cash Flow (TTM): approx. US$ 176M
The Acquirer’s Multiple (AM) of 2.82 positions Nutex in a statistically attractive value range, typically seen in distressed sectors. However, this does not accurately reflect Nutex’s growth trajectory.
Recent Financial Performance
Nutex has been showing strong profitability, with margins that are notable for healthcare operators. This is significant because improving profitability can lead to higher valuations.
Balance Sheet Insights
Looking at Nutex’s balance sheet:
- Total Assets: approx. US$ 655M
- Total Liabilities: approx. US$ 467M
- Shareholders’ Equity: approx. US$ 188M
- Total Debt: approx. US$ 341M
- Net Debt: approx. US$ 300M
Despite the leverage, it’s manageable and aligns with their expansion strategy given their solid cash flow.
Cash Flow and Efficiency
Nutex’s cash flow is a bright spot:
- Operating Cash Flow (TTM): approx. US$ 178M
- Free Cash Flow: approx. US$ 176M
High cash conversion from earnings and minimal maintenance costs hint at Nutex’s ability to fund its growth and potentially reduce debt.
Why NUTX Might Be Undervalued
Many believe the stock is undervalued due to various market concerns:
- As a small-cap operator, it has limited market coverage
- Complex relationships in joint ventures
- Uncertainties in reimbursement policies
- Rapid growth viewed as risky
However, the fundamentals tell a different story. With an AM of 2.82 and strong revenue, the company’s potential seems underestimated.
Conclusion
Nutex Health’s IV/P of 3.20 and AM of 2.82 suggest it is significantly undervalued in the healthcare sector. Its innovative approach to healthcare delivery aligns with current trends towards localized care. For investors willing to navigate the volatility of healthcare services, Nutex presents an interesting opportunity.
As the healthcare landscape continues to evolve, Nutex Health stands poised to capitalize on shifts towards more flexible care options, making it a stock worth watching closely.
